What is Zacks Research’s Forecast for CORT Q3 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research upped their Q3 2026 earnings per share estimates for shares of Corcept Therapeutics in a research report issued on Wednesday, August 19th. Zacks Research analyst Team now forecasts that the biotechnology company will earn $0.34 per share for the quarter, up from their prior estimate of $0.26. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.13 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2027 earnings at $0.66 EPS and Q4 2027 earnings at $0.63 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The company’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period last year, the company earned $0.29 EPS.

CORT has been the topic of a number of other reports. Piper Sandler reissued an “overweight” rating and issued a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday, July 27th. Truist Financial started coverage on shares of Corcept Therapeutics in a report on Tuesday. They issued a “buy” rating and a $164.00 target price for the company. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Price Performance

Shares of CORT stock opened at $119.02 on Thursday. The firm has a market cap of $12.87 billion, a PE ratio of 283.39 and a beta of 0.45. The company has a 50-day moving average of $95.84 and a two-hundred day moving average of $63.62. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $122.21.

Insider Activity at Corcept Therapeutics

In other news, Director James N. Wilson sold 10,000 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $111.43, for a total transaction of $1,114,300.00. Following the sale, the director owned 1,074,543 shares of the company’s stock, valued at approximately $119,736,326.49. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Guyer sold 16,300 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $113.43, for a total transaction of $1,848,909.00. Following the completion of the transaction, the insider directly owned 3,985 shares of the company’s stock, valued at approximately $452,018.55. The trade was a 80.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 416,540 shares of company stock valued at $36,652,354. 20.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Corcept Therapeutics in the second quarter valued at $1,080,964,000. First Trust Advisors LP boosted its holdings in Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after purchasing an additional 1,480,059 shares during the period. AQR Capital Management LLC grew its stake in Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after purchasing an additional 1,274,215 shares in the last quarter. Geode Capital Management LLC grew its stake in Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares in the last quarter. Finally, Norges Bank purchased a new stake in Corcept Therapeutics during the 4th quarter worth about $24,213,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.